Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Transducin β-like 1 X-linked receptor 1 (TBL1XR1) is a transcriptional cofactor implicated in various signaling pathways and cancer.
• Its specific role in carcinogenesis and tumor progression, particularly in nasopharyngeal carcinoma (NPC), remains unclear.

Purpose of the Study:

• To investigate the role of TBL1XR1 in nasopharyngeal carcinoma (NPC).
• To determine the association between TBL1XR1 expression and chemoresistance to cisplatin.
• To explore TBL1XR1 as a prognostic marker in NPC.

Main Methods:

• TBL1XR1 protein and mRNA expression were analyzed in NPC cell lines and patient biopsies using western blotting, real-time PCR, and immunohistochemistry.
• Chemoresistance to cisplatin was assessed in NPC cell lines in vitro and in vivo following TBL1XR1 overexpression.
• The NF-κB signaling pathway activation was investigated in relation to TBL1XR1 expression.

Main Results:

• TBL1XR1 was found to be upregulated in NPC cell lines and clinical samples.
• High TBL1XR1 expression correlated with advanced clinical stage, T classification, N classification, and poorer patient survival.
• Overexpression of TBL1XR1 conferred resistance to cisplatin-induced apoptosis in NPC cells, mediated by activation of the NF-κB pathway and increased transcription of anti-apoptotic genes.

Conclusions:

• Upregulated TBL1XR1 contributes to cisplatin resistance in NPC by activating the NF-κB pathway.
• TBL1XR1 expression is a significant independent prognostic factor for overall survival in NPC patients.
• TBL1XR1 represents a potential therapeutic target and biomarker for personalized treatment strategies in NPC.